Meta-analysis of the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer.

• Neoadjuvant chemotherapy (NACT) improves response rates, but not overall survival, in advanced cervical cancer. • Novel use of meta -analysis reveals the efficacy of preoperative NACT in young patients with cervical cancer. • NACT has limited impact on adverse effects; there is potential for individualized postoperative strategies. Neither improvements in surgical techniques and methods nor advances in radiotherapy equipment and techniques have significantly improved cervical cancer survival rates for quite some time. By comparing the effectiveness of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer, this study aimed to explore effective treatment methods for locally advanced cervical cancer, and provide a theoretical basis to guide clinical practice. A search of PubMed, Embase, Scopus, Web of Science and Cochrane databases was undertaken to identify randomized controlled trials on the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer, where the intervention in the experimental group was neoadjuvant chemotherapy. Based on the inclusion and exclusion criteria, the studies were evaluated for quality according to the Cochrane Quality Rating Scale. Baseline information, intervention information and outcome indicators of the included studies were extracted. Meta-analysis was performed using RevMan 5.4. Significant differences in overall survival [relative risk (RR) 1.63, 95 % confidence interval (CI) 0.69–2.57; p = 0.0007] and complete remission rate (RR 0.37, 95 % CI −0.49 to 1.23; p = 0.041) were found between the two groups. Heterogeneity of the objective response rate showed p < 0.0001 and I 2 = 99 % (I 2 = 99 > 50 % and p > 0.1 for the Q-test suggested strong heterogeneity). The fixed effects model was chosen for the integration statistic [standardized mean difference (SMD) 0.81, 95 % CI −0.21 to 1.83; p = 0.12]; the difference was not significant (p > 0.05). Heterogeneity of the adverse effects of neoadjuvant chemotherapy showed p < 0.0001 and I 2 = 98 % (I 2 = 98 %>50 % and p > 0.1 for the Q-test suggested strong heterogeneity). The fixed effects model was chosen for the integration statistic (SMD −0.023, 95 % CI −0.95 to 0.49; p = 0.53); the difference was not significant (p > 0.05). The use of neoadjuvant chemotherapy for the treatment of locally advanced cervical cancer improved the objective response rate and the complete remission rate of patients, but failed to improve overall survival and adverse effects. [ABSTRACT FROM AUTHOR]